Acute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia

Synapse

Volumn 65, Issue 4, 2011, Pages 339-350

  Crawford, Cynthia A ^a   Akopian, Garnik ^b   Ring, Justin ^b   Jakowec, Michael W ^c   Petzinger, Giselle M ^c   Andersen, Julie K ^d   Vittozzi Wong, Philip ^b   Wang, Kristie ^b   Farley, Cristal M ^a   Charntikov, Sergios ^a   Mitroi, Danut ^a   Beal, M Flint ^e   Chow, Robert ^c   Walsh, John P ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

3 NP; D 1 and D 2 receptors; DA release; Fast scan voltammetry; High performance liquid chromatography; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; MALONALDEHYDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN HYPOXIA; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; WALKING;

ANIMALS; ANOXIA; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; LIPID PEROXIDATION; MALE; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; SYNAPSES; TIME FACTORS;

EID: 79251552536     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20852     Document Type: Article

References (70)

1. Akopian G, Crawford C, Reichel CM, Beal MF, Cappelletti M, Jakowec MW, Petzinger G, Zheng L, Gheorghe SL, Chow R, Walsh JP. 2008. Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 hours after 3-nitropropionic acid induced chemical hypoxia. J Neurosci 28: 9585-9597.
2. Alexi T, Hughes PE, Faull RL, Williams CE. 1998. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeneration. Neuroreport 9: R57-R64.
3. 2 elevation, not ATP depletion. J Neurosci 25: 10029-10040.
4. Beal MF. 1994. Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 7: 542-547.
5. Beal MF. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366.
6. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. 1993a. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192.
7. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. 1993b. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61: 1147-1150.
8. Bhidayasiri R, Truong DD. 2004. Chorea and related disorders. Postgrad Med J 80: 527-534.
9. Blum D, Galas MC, Cuvelier L, Schiffmann SN. 2004. Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. Neurosci Lett 354: 234-238.
10. Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR. 1995. Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats. Brain Res Bull 36: 549-556.
11. Brouillet E, Jacqard C, Bizat N, Blum D. 2005. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95: 1521-1540.
12. Büyükuysal RL, Mete B. 1999. Anoxia-induced dopamine release from rat striatal slices: Involvement of reverse transport mechanism. J Neurochem 72: 1507-1515.
13. Centonze D, Usiello A, Costa C, Picconi B, Erbs E, Bernardi G, Borrelli E, Calabresi P. 2004. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci 24: 8214-8222.
14. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X. 2008. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28: 425-433.
15. Cowper-Smith CD, Anger GJ, Magal E, Norman MH, Robertson GS. 2008. Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 β inhibitor produces long-term neuroprotection in a hypoxia-ischemia model of brain injury. Neuroscience 155: 864-875.
16. 2-like binding sites, and dopamine content. Neurotox Teratol 22: 799-804.
17. Decker MJ, Jones KA, Solomon IG, Keating GL, Rye DB. 2005. Reduced extracellular dopamine and increased responsiveness to novelty: Neurochemical and behavioral sequelae of intermittent hypoxia. Sleep 28: 169-176.
18. Fancellu R, Armentero MT, Nappi G, Blandini F. 2003. Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurol Sci 24: 180-181.
19. Fernagut PO, Diguet E, Jaber M, Bioulac B, Tison F. 2002a. Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur J Neurosci 15: 2053-2056.
20. Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F. 2002b. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: Behavioural and histopathological characterization. Neuroscience 114: 1005-1017.
21. Filloux FM, Adair J, Narang N. 1996. The temporal evolution of striatal dopamine receptor binding and mRNA expression following hypoxia-ischemia in the neonatal rat. Dev Brain Res 94: 81-91.
22. Friedmann MN, Gerhardt GA. 1992. Regional effects of aging on dopaminergic function in the Fisher-344 rat. Neurobiol Aging 13: 325-332.
23. Garcia YJ, Rodriguez-Malaver AJ, Penaloza N. 2005. Lipid peroxidation measurement by thiobarbituric acid assay in rat cerebellar slices. J Neurosci Meth 144: 127-135.
24. Gil JM, Rego AC. 2008. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820.
25. 11C]raclopride positron emission tomography study in cats. Biol Psychiatry 55: 1188-1194.
26. 2+ channels. J Neurochem 99: 1197-1206.
27. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. 2001. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79: 152-160.
28. Gu W, Zhao H, Yenari MA, Sapolsky RM, Steinberg GK. 2004. Catalase over-expression protects striatal neurons from transient focal cerebral ischemia. Neuroreport 15: 413-416.
29. Hamilton BF, Gould DH. 1987. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage. Acta Neuropathol 72: 286-297.
30. Hashimoto N, Matsumoto T, Mabe H, Hashitani T, Nishino H. 1994. DA has inhibitory and accelerating effects on ischemia-induced neuronal cell damage in the rat striatum. Brain Res Bull 33: 281-288.
31. Hastings TG, Lewis DA, Zigmond MJ. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93: 1956-1961.
32. Jakel RJ, Maragos WF. 2000. Neuronal cell death in Huntington's disease: A potential role for dopamine. Trends Neurosci 23: 239-245.
33. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann Neurol 44: S72-S84.
34. Johnson JR, Robinson BL, Ali SF, Binienda Z. 2000. Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats. Toxicol Lett 116: 113-118.
35. Johnson MA, Villanueva M, Haynes CL, Seipel AT, Buhler LA, Wightman RM. 2007. Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice. J Neurochem 103: 2102-2110.
36. Kim GW, Chan PH. 2002. Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. J Cereb Blood Flow Metab 22: 798-809.
37. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. 2000. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. J Neurosci 20: 1-7.
38. Kostic VS, Przedborski S, Jackson-Lewis V, Cadet JL, Burke RE. 1991. Effect of unilateral perinatal hypoxic-ischemic brain injury on striatal dopamine uptake sites and D1 and D2 receptors in adult rats. Neurosci Lett 129: 197-200.
39. Kraft JC, Osterhaus GL, Ortiz AN, Garris PA, Johnson MA. 2009. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid. Neuroscience 161: 940-949.
40. Kumar P, Kumar A. 2009. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 33: 100-108.
41. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227: 680-685.
42. Lancelot E, Callebert J, Revaud ML, Boulu RG, Plotkine M. 1995. Detection of hydroxyl radicals in rat striatum during transient focal cerebral ischemia: Possible implication in tissue damage. Neurosci Lett 197: 85-88.
43. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF. 2004. Genetic mouse models of Huntington's and Parkinson's diseases: Illuminating but imperfect. Trends Neurosci 27: 691-697.
44. Lowry OH, Rosenbrough NG, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 93: 265-275.
45. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 1991. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurolog Sci 18: 492-498.
46. Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C, Morari M. 2003. Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: Implications for Huntington's disease. Eur J Neurosci 18: 759-767.
47. Meade CA, Figueredo-Cardenas G, Fusco F, Nowak TSJr, Pulsinelli WA, Reiner A. 2000. Transient global ischemia in rats yields striatal projection neurons and interneuron loss resembling that in Huntington's disease. Exp Neurol 166: 307-323.
48. Miles PR, Mundorf ML, Wightman RM. 2002. Release and uptake of catecholamines in the bed nucleus of the stria terminalis measured in the mouse brain slice. Synapse 44: 188-197.
49. National Research Council. 2003. Guidelines for the care and use of mammals in neuroscience and behavioral research. Washington, DC: National Academy Press.
50. Nishino H, Hida H, Kumazaki M, Shimano Y, Nakajima K, Shimizu H, Ooiwa T, Baba H. 2000. The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: A hypothesis to explain its specific vulnerability. J Neurotrauma 17: 251-260.
51. Nishino H, Kumazaki M, Fukuda A, Fujimoto I, Shimano Y, Hida H, Sakurai T, Deshpande SB, Shimizu H, Morikawa S, Inubushi T. 1997. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: Involvement of dopamine toxicity. Neurosci Res 27: 343-355.
52. Orset C, Parrot S, Sauvinet V, Cottet-Emard JM, Pequignot JM, Denoroy L. 2006. NMDA receptors inhibit the mild hypoxia-induced dopamine efflux in the rat striatum. Synapse 59: 458-461.
53. Pang ZP, Ling GY, Gajendiran M, Xu ZC. 2002. Asymmetrical changes of excitatory synaptic transmission in dopamine-denervated striatum after transient forebrain ischemia. Neuroscience 114: 317-326.
54. Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA. 2003. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 85: 898-910.
55. Patel J, Rice ME. 2006. Monitoring dopamine release in brain slices. In: Grimes CA, Dickey EC, Pishko MV, editors. Encyclopedia of sensors. Stevenson Ranch, CA: American Scientific Publishers. p 313-334.
56. Paxinos G, Watson C. 1998. The rat brain: in stereotaxic coordinates. San Diego, CA: Academic Press.
57. Pereyra-Muñoz N, Rugerio-Vargas C, Angoa-Pérez M, Borgonio-Pérez G, Rivas-Arancibia S. 2006. Oxidative damage in substantia nigra and striatum of rats chronically exposed to ozone. J Chem Neuroanat 31: 114-123.
58. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Fisher BE, Togasaki D, Jakowec ME. 2007. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-(MPTP)-lesioned mouse model of basal ganglia injury. J Neurosci 27: 5291-5300.
59. 2 receptors and uptake sites: A quantitative autoradiographic study. J Neurochem 57: 1951-1961.
60. Rees JN, Florang VR, Anderson DG, Doorn JA. 2007. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem Res Toxicol 20: 1536-1542.
61. Ren Y, Li X, Xu ZC. 1997. Asymmetrical protection of neostriatal neurons against transient forebrain ischemia by unilateral dopamine depletion. Exp Neurol 146: 250-257.
62. Reynolds DS, Carter RJ, Morton AJ. 1998. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 18: 10116-10127.
63. Schulte A, Chow RH. 1996. A simple method for insulating carbon-fiber microelectrodes using anodic electrophoretic deposition of paint. Anal Chem 68: 3054-3058.
64. 3H](+)PHNO. Synapse 61: 263-267.
65. 2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46: 235-239.
66. Ste-Marie L, Vachon P, Vachon L, Bémeur C, Guertin M-C, Montgomery J. 2000. Hydroxyl radical production in the cortex and striatum in a rat model of focal cerebral ischemia. Can J Neurol Sci 27: 152-159.
67. 3H]spiperone. Mol Pharmacol 63: 456-462.
68. Toner CC, Stamford JA. 1999. Effects of metabolic alterations on dopamine release in an in vitro model of neostriatal ischaemia. Brain Res Bull 48: 395-399.
69. Yang Z-J, Camporesi C, Yang X, Wang J, Bosco G, Lok J, Reza G, Schelper RL, Camporesi EM. 2002. Hyperbaric oxygen mitigates focal cerebral injury and reduces striatal dopamine release in a rat model of transient middle cerebral artery occlusion. Eur J Appl Physiol 87: 101-107.
70. Zouakia A, Guilloteau D, Zimmer L, Besnard JC, Chalon S. 1997. Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: Autoradiographic studies. Life Sci 60: 151-162.